Overview

Update
IPO / Stock
Went Public on Jul 24, 2013 / NASDAQ:HTBX
Total Equity Funding
$8.1M in 3 Rounds
Headquarters:
Chapel Hill, NC
Description:
Heat Biologics, a clinical-stage company, offers ImPACT, an adjuvant technology to identify oncology and infectious disease indications.
Founders:
Categories:
Health Care, Biotechnology, Medical
Website:
http://heatbio.com
Social:

Company Details

Update

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) adjuvant technology for use in a number of oncology and infectious disease indications. Heat’s ImPACT therapy is a first-in-class fully human adjuvant system that functions as both an immune stimulator and an antigen-delivery system. ImPACT is rapidly applied to a selected off-the-shelf cancer cell line to effectively transform living tumor into powerful machines that “pump out” their full antigenic fingerprint to robustly stimulate the immune system against the targeted disease. ImPACT is applicable to a wide range of cancers as well as infectious diseases including HIV, HCV and malaria. Heat is currently in Phase II clinical trials with its first drug to treat Non Small Cell Lung Cancer (NSCLC) and plans to initiate clinical trials against additional cancers in 2012.

Funding Rounds (4) - $15.6M

Update
DateAmount / RoundValuationLead InvestorInvestors
Aug, 2014$7.5M / Post Ipo Debt1
Apr, 2013$5.05M / Private Equity0
May, 2012$2.8M / Series A0
Nov, 2009$249.75k / Venture0

Investors (1)

InvestorRound(s)Partner(s)
Post Ipo Debt-

Current Team (8)

Update

Offices/Locations (1)

Update
  • Headquarters

    100 Europa Drive

    Suite 420

    Chapel Hill, NC 27517

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos